Carmat fell 19% this Monday morning on the Paris Stock Exchange, to 19.60 euros. Medtech announced on Friday after the close, to temporarily suspend the implantation of its artificial heart Aeson® after the discovery of a quality problem on some of its prostheses. Investigations are underway, indicates management. She will communicate later on the resumption of the establishments.

“Following the occurrence of a quality problem which affected some of its prostheses, the company decided to temporarily suspend, as a preventive measure, the implantations of its Aeson artificial heart”, declares Carmat.

“While waiting to have more visibility on this event, we suspend our recommendation on the title”, indicates the firm Portzamparc in its morning note. For Invest Securities, “depending on the length of time the quality issue is investigated and resolved, the suspension may affect the schedule. “

Carmat expects the finalization of the recruitment of the European pivotal study by the end of the first half of 2022. On the EFICAS study which will assess 52 locations in France, the medtech plans to recruit from the fourth quarter of this year in 6 centers , recalls the analysts office.

Carmat had just completed the first implantation of his artificial heart in the Netherlands. This brought the number of implantations carried out to 16, out of the 20 in the company’s PIVOT study. A little less than two months ago, the group announced the first transplant in a woman. It was performed in the United States at the University of Louisville-Health Jewish Hospital, Kentucky, in a 57-year-old patient with severe biventricular heart failure who had had heart surgery several years previously.

Also in mid-September, Carmat had presented half-yearly loss accounts, admittedly slightly increased, but under the impact of the needs linked to the ramp-up of production and the strengthening of the commercial structure. For the Portzamparc firm, the period was “marked by the preparation of the first commercial sales of Aeson® and therefore by the increase in costs linked to the ramp-up of production and the establishment of the structure. commercial ”.

EUROFINS SCIENT. : Amid the hubbub of speculation surrounding Omicron, the stock market chooses to hear the latest reassuring statements

THERADIAG: Great ambitions for Theradiag and a speculative dimension

MANUTAN INTL: Manutan delivers more than solid financial results for fiscal year 2020-2021

AMPLITUDE SURGICAL: Amplitude Surgical records a decrease in its turnover in the first quarter

PRODWAYS: Prodways signs a very promising new partnership

Saint-Gobain acquires the construction chemicals group GCP for 2 billion euros

Saint-Gobain acquires the construction chemicals group GCP for 2 billion euros

Related title :
Carmat suspends l& # 39; implantation of its artificial hearts and plunges into the stock market
To be continued today& # 39; today. .. Carmat